



Aus dem Institut für Molekulare Onkologie 
(Prof. Dr. med. M. Dobbelstein) 







zur Erlangung des Doktorgrades 
der Medizinischen Fakultät der 







Accumulation of  single-stranded DNA 


























Dekan: Prof. Dr. rer. nat. H. K. Kroemer 
Referent/in Prof. Dr. med. M. Dobbelstein 
Ko-Referent/in:  Prof. Dr. med. H. Hahn 
Drittreferent/in:  
 














Hiermit erkläre ich, die Dissertation mit dem Titel 
"Accumulation of single-stranded DNA in tumour cells as a 
result of replicative stress" eigenständig angefertigt und keine 
anderen als die von mir angegebenen Quellen und Hilfsmittel 
verwendet zu haben.  
 
Göttingen, den ……………           …………………………… 










Table of Contents I 
Table of  Contents 
 
Publication of the Results ......................................................................................... III 
Index of Figures .......................................................................................................... V 
Index of Tables .......................................................................................................... VI 
Index of Abbreviations............................................................................................. VII 
1 Introduction ............................................................................................................ 1 
1.1 DNA damage and its role in cancer ..................................................................................................... 1 
1.1.1 The principle of chemotherapy .......................................................................................................... 1 
1.1.2 Nucleoside analogues and antimetabolites ....................................................................................... 2 
1.1.3 Sensitizing cancer cells for chemotherapy........................................................................................ 3 
1.2 Replicative stress and the DNA damage response ............................................................................ 3 
1.2.1 Regulation of DNA replication.......................................................................................................... 5 
1.2.2 A response to ssDNA: ATR Chk1 pathway .................................................................................... 5 
1.2.3 A response to DSBs: ATM Chk2 pathway ...................................................................................... 7 
1.2.4 Phosphorylation of H2AX ................................................................................................................. 7 
1.2.5 The cell cycle and its regulation ......................................................................................................... 8 
1.2.6 The intra-S phase checkpoint ............................................................................................................. 8 
1.2.7 Induction of apoptosis ........................................................................................................................ 9 
1.3 The G2 specific E3 ligase (G2E3) ...................................................................................................... 10 
1.4 The MAPKAP Kinase MK2 ............................................................................................................... 11 
1.5 Aims of this study ................................................................................................................................. 12 
2 Materials and Methods ........................................................................................ 13 
2.1 Materials .................................................................................................................................................. 13 
2.1.1 Buffers and Solutions ........................................................................................................................ 13 
2.1.2 Chemotherapeutics and Inhibitors .................................................................................................. 15 
2.1.3 Kits ....................................................................................................................................................... 16 
2.1.4 Small interfering RNAs ..................................................................................................................... 16 
2.1.5 Antibodies ........................................................................................................................................... 17 
2.1.6 Cell culture .......................................................................................................................................... 18 
2.2 Methods .................................................................................................................................................. 19 
2.2.1 Human cell culture ............................................................................................................................. 19 
2.2.2 Western blot ........................................................................................................................................ 22 
2.2.3 High content immunofluorescence microscopy ........................................................................... 23 
2.2.4 BrdU assay for ssDNA ...................................................................................................................... 24 
2.2.5 Statistical analysis................................................................................................................................ 25 
Table of Contents II 
3 Results .................................................................................................................. 26 
3.1 The BrdU assay detects ssDNA ......................................................................................................... 26 
3.1.1 Only one antibody to BrdU reliably detects its epitope upon replicative stress in a high-
content semi-automated setup ........................................................................................................ 27 
3.1.2 ssDNA is not mainly generated as a result of increased apoptosis ............................................ 29 
3.1.3 The BrdU signal correlates with γ-H2AX ...................................................................................... 30 
3.2 The ubiquitin ligase G2E3 plays a role in replicative stress ........................................................... 31 
3.2.1 Knockdown of G2E3 leads to an accumulation of ssDNA ....................................................... 33 
3.2.2 Knockdown of G2E3 decreases levels of phosphorylated Chk1............................................... 35 
3.3 MK2 inhibition rescues accumulation of ssDNA and γ-H2AX upon gemcitabine 
treatment ............................................................................................................................................. 37 
4 Discussion ............................................................................................................ 40 
4.1 The BrdU assay as a method to assess replicative stress ................................................................ 40 
4.1.1 Limitations and outlook .................................................................................................................... 42 
4.2 G2E3 in the response to DNA damage ............................................................................................ 42 
4.2.1 G2E3 as a potential target for chemosensitisation ....................................................................... 43 
4.2.2 Open questions and outlook ............................................................................................................ 44 
4.3 MK2 and chemoresistance................................................................................................................... 45 
5 Abstract ................................................................................................................ 46 
6 Literature .............................................................................................................. 47 
Publication of the Results III 
Publication of  the Results 
The results of this work are published in Proceedings of the Natural Academy of Sciences (Köpper 
et al. 2013) and Oncotarget (Schmidt et al. 2015): 
 
Damage induced DNA replication stalling relies on 
 MAPK-activated protein kinase 2 activity 
Frederik Köpper1, Cathrin Bierwirth1, Margarete Schön2, Meike Kunze1, Ingegerd Elvers3, 
Dominique Kranz4, Priyanka Saini1, Manoj B. Menon5, David Walter6, Claus Storgaard 
Sørensen6, Matthias Gaestel5, Thomas Helleday7, Michael P. Schön2, and Matthias 
Dobbelstein1 
1Institute of Molecular Oncology and Göttingen Centre of Molecular Biosciences, Faculty of 
Medicine, University of Göttingen, 37077 Göttingen, Germany 
2Department of Dermatology, Venereology and Allergology, Faculty of Medicine, University of 
Göttingen, 37099 Göttingen, Germany 
3Department of Genetics, Microbiology and Toxicology, Stockholm University, S-106 91 
Stockholm, Sweden 
4Institute for Medical Biology, University of Southern Denmark, 5230 Odense, Denmark 
5Institute of Biochemistry, Hannover Medical School, 30623 Hannover, Germany 
6Biotech Research and Innovation Centre, University of Copenhagen, 2200 Copenhagen, 
Denmark 
7Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, 
Department of Medical Biochemistry and Biophysics, Karolinska Institute, SE-171 77 Solna, 
Sweden 
Abstract 
DNA damage can obstruct replication forks, resulting in replicative stress. By siRNA 
screening, we identified kinases involved in the accumulation of phosphohistone 2AX 
(γH2AX) upon UV irradiation-induced replication stress. Surprisingly, the strongest 
reduction of phosphohistone 2AX followed knockdown of the MAP kinase-activated 
protein kinase 2 (MK2), a kinase currently implicated in p38 stress signaling and G2 arrest. 
Depletion or inhibition of MK2 also protected cells from DNA damage-induced cell death, 
and mice deficient for MK2 displayed decreased apoptosis in the skin upon UV irradiation. 
Moreover, MK2 activity was required for damage response, accumulation of ssDNA, and 
decreased survival when cells were treated with the nucleoside analogue gemcitabine or 
when the checkpoint kinase Chk1 was antagonized. By using DNA fiber assays, we found 
that MK2 inhibition or knockdown rescued DNA replication impaired by gemcitabine or 
by Chk1 inhibition. This rescue strictly depended on translesion DNA polymerases. In 
conclusion, instead of being an unavoidable consequence of DNA damage, alterations of 
replication speed and origin firing depend on MK2-mediated signaling. 
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Screening analysis of ubiquitin ligases reveals G2E3 as a potential target for 
chemosensitizing cancer cells 
Franziska Schmidt1, Meike Kunze1, Ann-Christine Loock1, Matthias Dobbelstein1 
1Institute of Molecular Oncology and Göttingen Centre of Molecular Biosciences, Faculty of 
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Abstract 
Cisplatin is widely used against various tumors, but resistance is commonly encountered. 
By inducing DNA crosslinks, cisplatin triggers DNA damage response (DDR) and cell 
death. However, the molecular determinants of how cells respond to cisplatin are 
incompletely understood. Since ubiquitination plays a major role in DDR, we performed a 
high-content siRNA screen targeting 327 human ubiquitin ligases and 92 deubiquitinating 
enzymes in U2OS cells, interrogating the response to cisplatin. We quantified γH2AX by 
immunofluorescence and image analysis as a read-out for DNA damage. Among known 
mediators of DDR, the screen identified the ubiquitin ligase G2E3 as a new player in the 
response to cisplatin. G2E3 depletion led to decreased γH2AX levels and decreased 
phosphorylation of the checkpoint kinase 1 (Chk1) upon cisplatin. Moreover, loss of G2E3 
triggered apoptosis and decreased proliferation of cancer cells. Treating cells with the 
nucleoside analogue gemcitabine led to increased accumulation of single-stranded DNA 
upon G2E3 depletion, pointing to a defect in replication. Furthermore, we show that 
endogenous G2E3 levels in cancer cells were down-regulated upon chemotherapeutic 
treatment. Taken together, our results suggest that G2E3 is a molecular determinant of the 
DDR and cell survival, and that its loss sensitizes tumor cells towards DNA-damaging 
treatment. 
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1 Introduction 
1.1 DNA damage and its role in cancer 
The genomic information contained in every living cell is a highly protected good that is 
given from one generation of cells to the next and whose integrity is a requirement for the 
healthy formation of tissues, organs and organisms. But even under normal circumstances, 
every cell is constantly subjected to DNA damage. The main part of this damage is 
endogenous in nature, so originating from within the cell itself. Most frequently, it is due to 
Reactive Oxygen Species (ROS) that are constantly generated as a by-product of a cell’s 
metabolism (Bont and Larebeke 2004). Opposed to this, exogenous damage stems from a 
source outside of the cell. Examples include ultraviolet or ionising irradiation, chemicals 
such as formaldehyde or chemotherapeutic drugs. For them the induction of DNA damage 
is the very principle of their therapeutic effect. Of course, this damage needs to be sensed 
and somehow responded to by the cell. A signalling cascade termed the DNA damage 
response (DDR) does exactly this sensing and there are several repair mechanisms to 
rectify DNA damage once it is done. However, sometimes damage can be very severe or 
the sensing and repair mechanisms can fail. In these cases, either apoptosis, programmed 
cell death, is induced (Norbury and Zhivotovsky 2004) or the cell starts to accumulate 
damage in form of mutations and even passes it on to daughter cells resulting in genomic 
instability and eventually leading to the development of cancer. 
1.1.1 The principle of chemotherapy 
Chemotherapy together with surgery, radiotherapy and more recently emerging targeted 
approaches is one of the cornerstones of cancer therapy. It was first introduced in the 
middle of the 20th century and remains to be of enormous clinical significance (DeVita and 
Chu 2008). Nowadays, there are several different chemotherapeutics which can be divided 
into categories based on their chemical structure and mechanism of action and include, but 
are not limited to alkylating agents, topoisomerase inhibitors and antimetabolites or 
nucleoside analogues (Helleday et al. 2008). Most of these groups have in common that 
they somehow interfere with the normal replication of a cell; others possess direct toxic 
activity. Cancer cells are especially susceptible to perturbed replication; firstly because of 
their high replicational activity and secondly because they are genetically instable, 
particularly in the advanced stages of cancer, and have already accumulated mutations that 
impair the sensing and repair mechanisms employed by healthy cells (Kotsantis et al. 2015). 
Therefore, treatment with chemotherapeutics will lead to the death of a cell or the 
induction of cell cycle arrest in a higher percentage of cancer cells than it does in normal 
cells. 
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1.1.2 Nucleoside analogues and antimetabolites 
Antimetabolites are drugs that interfere with other naturally occurring substances that are 
generated and used in the normal metabolism of a cell. Often, but not always, 
antimetabolites closely resemble the metabolite with which they are interfering. A subgroup 
of antimetabolites are nucleoside analogues that resemble either pyrimidines or purines and 
can be incorporated into the DNA in their place. Nucleoside analogues are S-phase-specific 
drugs as they only work on cells that are currently replicating their DNA (Ewald et al. 
2008).  
Other antimetabolites inhibit enzymes that are responsible for the generation of 
deoxyribonucleotides (dNTPs). Often targeted enzymes are dihydrofolate reductase or 
ribonucleotide reductase (RNR). Their inhibition results in imbalances within the dNTP 
pool of a cell and can for example lead to a shortage of nucleotides (Helleday et al. 2008). 
One example used in this study is hydroxyurea (HU) that is an antimetabolite but not a 
nucleoside analogue and acts as an inhibitor of RNR (Krakoff et al. 1968). Although, there 
are hints that HU may also interfere with later processes during DNA replication as cells 
seem to accumulate in early S phase and not at the G1/S boundary as one would assume 
(Wawra and Wintersberger 1983). 
1.1.2.1 Gemcitabine  
Gemcitabine or 2’,2’-difluoro 2’-deoxycytidine is an analogue of deoxycytidine which is 
incorporated into the DNA during replication leading to chain termination one nucleotide 
after the incorporation side. Its structure is depicted in Figure 1. Gemcitabine is a prodrug, 
in order to be incorporated into the DNA, it needs to be phosphorylated by 
deoxycytidinkinase thrice to its triphosphate form. Once gemcitabine is incorporated, the 
DNA polymerase adds one more nucleotide to the nascent strand but then fails to elongate 
it any further because of the steric deformation of the strand which does no longer fit into 
the polymerase’s catalytic site (Konerding et al. 2002). This process is called masked chain 
termination and gemcitabine’s penultimate position in the DNA strand prevents the 
immediate correction by the polymerase’s attached exonuclease and also hinders correction 
by other DNA repair mechanisms (Schy et al. 1993; Crul et al. 2003). Additionally, 
gemcitabine inhibits the enzyme ribonucleotide reductase (RNR) (Huang et al. 1991; Mini 
et al. 2006), further increasing its cytotoxic potential by causing a decrease in the number of 
available deoxynucleotides. This in turn leads to a shift within the available supply of 
deoxycytidine and gemcitabine, shifting the balance more towards the drug and allowing 
more gemcitabine to be incorporated, a process called self-potentiation (Ewald et al. 2008). 
Gemcitabine is most importantly used in pancreatic cancer (Burris et al. 1997) but is also a 
part of treatment protocols for advanced cases of non small cell lung cancer (NSCLC), 
bladder cancer and breast cancer (Ewald et al. 2008). 
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Figure 1: Structure of gemcitabine as opposed to deoxycytidine 
Gemcitabine differs from deoxycytidine in its two fluorine substituents on position 2’ of 
the furanose ring and leads to masked chain termination once it is incorporated into the 
DNA. 
1.1.3 Sensitizing cancer cells for chemotherapy 
Cancer cells are characterised by genomic instability, activation of oncogenes and 
inactivation of tumour suppressors, increasing for example proliferation rates but at the 
same time leading to an attenuated response and ability to sense and repair DNA damage. 
On the one hand, this favours a higher mutation rate, further increasing their malignancy; 
on the other hand, it abrogates sensing and repair pathways that are especially important 
for survival if cells are treated with chemotherapy. Therefore, cancer cells often 
compensate this loss by using alternative sensing and repair pathways to avoid cell death. 
Consequently, the externally driven disruption of other pathways in addition to standard 
chemotherapy can lead to a much higher percentage of cells that are no longer able to 
adequately react to DNA damage and are driven towards cell death, while non-cancerous 
cells still have alternative mechanism to avoid severe damage (Helleday et al. 2008; Tian et 
al. 2015). This principle is known as chemosensitisation. Promising targets for 
chemosensitisation are proteins involved in DNA repair or in checkpoint signalling like 
ATM, ATR, Chk1 and Chk2 (see 1.2.2 and 1.2.3). For two different inhibitors of Chk1 
(one of them UCN-01 which was also used in this study) there are already clinical trials in 
patients with advanced stages of cancer (Welch et al. 2007; Helleday et al. 2008; 
Dobbelstein and Sørensen 2015). 
1.2 Replicative stress and the DNA damage response 
Replicative stress is a loosely defined term used to describe DNA damage that interferes 
with on-going replication, thus impeding correct and timely completion of S phase (see 
1.2.5 and 1.2.6 for details). A characteristic of replicative stress is the formation of stalled 
and collapsed replication forks (Dobbelstein and Sørensen 2015). Sources of replicative 
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stress can be DNA lesions, ribonucleotides that have been incorporated instead of 
desoxyribonucleotides, imbalances in the dNTP pool of a cell, repetitive DNA structures, 
oncogene induced stress and several others. So, the obstacles posed to replication can be of 
various nature but all result in the inability of the replisome (see 1.2.1) to move further 
along the DNA strand, thus causing what is called a stalled replication fork. This stalled 
fork can be restarted once the obstacle, e.g. a chemically modified base, is removed but if 
this is not achieved in a timely manner, the replisome can dissociate from the DNA strand 
or be no longer functional, giving rise to a collapsed replication fork. Collapsed forks 
cannot be restarted even if the damage that caused them is repaired later on (Zeman and 
Cimprich 2014). Cells have developed several mechanisms to cope with replicative stress 
and in principle, three different outcomes are possible: Repair of the damaged DNA and 
completion of replication, cell cycle arrest or the induction of apoptosis (see Figure 2 for a 
schematic overview). 
 
Figure 2: Sources and consequences of replicative stress 
Various occurrences can pose obstacles to on-going replication, leading to fork stalling. A 
stalled fork can either be restarted or collapses after a short period of time. Once collapsed 
the DNA damage response comes into action and can lead to either DNA repair, induction 
of cell cycle arrest or programmed cell death. Blue ovals depict parts of the replication 
machinery. 
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To understand the causes and consequences of replicative stress, it is necessary to first look 
at how DNA replication is normally organised and regulated and then focus on the 
response to disturbances during this process. The following sections will provide a brief 
overview of these topics. 
1.2.1 Regulation of DNA replication 
In eukaryotic cells, as opposed to prokaryotes, replication does not start at a predefined 
point of the genome, but at several different and seemingly randomly distributed 
replication origins. Before S phase, these origins need to be licensed, which means that 
several proteins including the minichromosome maintenance2-7 (MCM2-7) helicase 
complex are recruited that together form the pre-Replicative Complex (pre-RC), basically a 
still inactive replication machinery. Upon the onset of S phase, a small portion of 
approximately 10 % of these origins are fired, meaning that MCM2-7 is phosphorylated 
and several proteins including DNA-polymerase primase α are recruited to the now active 
origin. The firing of an origin results in the formation of a bidirectional replication bubble 
with two replisomes moving away from their origin (Masai et al. 2010). 
If replication at one of these forks comes to a halt and cannot be resumed, this gives rise to 
a collapsed replication fork. A possibility to ensure complete replication in this case is the 
firing of one of the previously unfired, so-called dormant origins on the other side of the 
lesion. The mechanisms behind this are still not completely understood and it remains 
unclear whether firing of dormant origins in response to replicative stress is a purely 
stochastic process or occurs in a regulated manner (McIntosh and Blow 2012). 
1.2.2 A response to ssDNA: ATR Chk1 pathway 
Upon stalling of a replication fork, helicase continues to unwind the DNA but the 
polymerase fails to elongate the nascent strand any further, thereby creating stretches of 
single-stranded DNA (as shown in Figure 5). The ssDNA is quickly coated with replication 
protein A (RPA) that further recruits ATR-interacting-protein (ATRIP) to these sites (Zou 
and Elledge 2003). ATRIP then serves as a binding partner for ATR (ATM (ataxia 
teleangiectasia mutated)-and-Rad3-related) (Branzei and Foiani 2009). ATR, together with 
ATM (discussed in detail in 1.2.3) and DNA-dependent protein-kinase (DNA-PK) is one 
of the key kinases of the DNA damage response. All three are serin/threonine kinases and 
belong to the family of nuclear phosphatidylinositol-3-kinase-related-kinases serin/threonin 
kinases (PIKK-family); ATM mainly mediates the response to DNA double-strand breaks 
and is discussed in detail below. An overview of ATR as well as ATM signalling can be 
found in Figure 3. 
Once ATR is recruited to ssDNA it phosphorylates a wide range of substrates, one of the 
most important ones being checkpoint-kinase 1 (Chk1) (Zhao and Piwnica-Worms 2001). 
Chk1 is mostly present in S and G2 phase and even in the absence of DNA damage it is 
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active at a low level (Lukas et al. 2001; Bartek and Lukas 2003). ATR is the main activator 
of Chk1 but Chk1 can also be phosphorylated by ATM and possibly other kinases in a 
process known as crosstalk (Gatei et al. 2003). Chk1 then goes on to phosphorylate a 
plethora of substrates thereby distributing and amplifying the transduced signal. Apoptosis, 
chromatin remodelling, progression through the cell cycle, DNA repair and stabilisation of 
stalled replication forks are all subject to regulation via the ATR/Chk1 pathway. Both 
ATR, as well as Chk1 are essential for mammalian development and their complete loss 
results in early embryonic lethality in mice (Brown and Baltimore 2000; de Klein et al. 2000; 
Takai et al. 2000). The constant low-level activation of the ATR-Chk1 pathway seems to be 
necessary to suppress excessive origin firing during normal S phase (Shechter et al. 2004). If 
completely activated at a stalled fork, ATR-Chk1 signalling stabilises the stalled fork and 
allows a cell to repair the DNA damage and eventually restart the stalled fork by halting the 
cell’s progression through the cell cycle. This function is part of the intra-S phase 
checkpoint and will be discussed in more detail below (1.2.6). 
 
Figure 3: Schematic depiction of major signalling pathways in the DNA damage response 
The ATR/Chk1 pathway mainly responds to the exposure of ssDNA at stalled replication 
forks, the ATM/Chk2 pathway is activated upon the detection of DNA double strand 
breaks. Both Chk1 and Chk2 phosphorylate a great number of targets. Their signalling can 
lead to apoptosis, DNA repair, the activation of cell cycle checkpoints and chromatin 
remodelling, depending on the type and severity of damage. Both pathways can activate 
and influence each other at different stages of the signalling process. 
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1.2.3 A response to DSBs: ATM Chk2 pathway 
ATM, as already introduced above, is mainly activated upon DNA double strand breaks 
that can also be the product of collapsed replication forks following replicative stress 
(Hanada et al. 2007) but mostly occur after treatment with DNA damaging agents like 
topoisomerase II inhibitors or irradiation. ATM in its inactive form is a dimer that upon 
autophosphorylation dissociates into two active monomers and locates to the sites of DSB 
with the help of several adaptor proteins (Bakkenist and Kastan 2003). One protein 
phosphorylated by ATM is Checkpoint kinase 2 (Chk2) that largely functions in parallel to 
Chk1 and phosphorylates substrates like p53 and others known to be essential for cell cycle 
control and the induction of apoptosis. ATM itself also targets p53 via its negative 
regulator Mouse double minute 2 homologue (Mdm2) and further controls two pathways 
needed for the repair of DSBs – non-homologous end joining (NHEJ) and homologous 
recombination (HR) (Ciccia and Elledge 2010). 
The tumour suppressor p53 has a central role in the response to DNA damage and also to 
more general sources of cellular stress. This key function is further illustrated by the finding 
that p53 is mutated in approximately 50 % of all human malignancies (Hollstein et al. 
1991). It belongs to a protein family together with p73 and p63 and serves as a 
transcription factor for genes involved in cell-cycle-arrest, apoptosis and DNA repair 
(Menendez et al. 2009). P53 is always present in a cell but is normally kept at relatively low 
levels via ubiquitination and consequent proteosomal degradation. Upon phosphorylation 
by for example ATM, ATR, Chk1 or Chk2 it is stabilised and accumulates, forming a 
tetramer that then serves as the active transcription factor (Oren 2003). 
1.2.4 Phosphorylation of H2AX 
In every cell the DNA is wound around histones and thusly organised into structures that 
we call nucleosomes. But histones do not only package DNA, they also influence its 
accessibility for other proteins. Histone 2AX (H2AX) is a histone variant that is 
phosphorylated upon DNA damage and plays a role in the recruitment of proteins like 
those involved in DSB repair by homologous recombination and non homologous end-
joining to the site of damage (Hartlerode and Scully 2009). The phosphorylation occurs 
specifically at Serine 139 of H2AX that is called γ-H2AX in its phospho-form. All three 
major sensing-kinases of the DNA damage response ATM, ATR and DNA-PK are shown 
to catalyse this posttranslational modification (Burma et al. 2001; Stiff et al. 2004; Ward et 
al. 2004). The phosphorylation of H2AX spreads along the DNA strand and serves as a 
signal amplifier for the DDR. Especially ATM is recruited to sites of γ-H2AX and further 
activated (Stucki and Jackson 2006; Cimprich and Cortez 2008). Due to these properties 
and easy staining in immunofluorescence, γ-H2AX is a well established and much used 
marker for DNA damage in general. 
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1.2.5 The cell cycle and its regulation 
Most cells follow a regular and tightly controlled life cycle leading to replication of their 
DNA and subsequent cell division. To ensure that no vital errors occur during the process, 
this cell cycle includes several checkpoints that can, in case of problems, halt a cell’s 
progression through the cell cycle and allow time for repair. A normal cell cycle consists of 
Gap 1 (G1) phase where cells grow and prepare for replication, S phase during which the 
DNA is replicated, Gap2 (G2) phase that is characterised by further cell growth and M 
phase or mitosis where the cell divides into two daughter cells. There are three major 
checkpoints that can be activated as a consequence of DNA damage: the G1/S, the intra-S 
phase and the G2/M checkpoint (Morgan 2006). The underlying principle of regulation for 
all the checkpoints is the same. In order to progress, a kinase of the so-called cyclin 
dependant kinases (CDKs) is needed to phosphorylate effector proteins. As suggested by 
their name, CDKs need cyclins to be active and transcription of cyclins is tightly controlled 
and only occurs during certain phases of the cell cycle and once certain requirements are 
met. Once CDKs and Cyclins form a complex, it needs to be phosphorylated in order to 
be fully active and to allow the cell to progress further through the cell cycle. 
The G1/S as well as the G2/M checkpoints are mainly p53 dependant. As described above 
(see 1.2.3), p53 is stabilised as a consequence of DNA damage signalling for example via 
the ATR or ATM pathway. Upon accumulation of p53 it induces transcription of p21 and 
others that in turn inhibit Cyclin/CDK complexes thus hindering entry into the next cell 
cycle phase (el-Deiry et al. 1993; Harper et al. 1993). 
1.2.6 The intra-S phase checkpoint 
The intra-S phase checkpoint is crucial for maintaining genomic stability under conditions 
of replicative stress. As detailed above (1.2.2), ATR and Chk1 will be activated upon DNA 
damage that interferes with replication and leads to stalled replication forks. Chk1 
phosphorylates and inactivates Cdc25 phosphatases and activates Wee1 leading to cell cycle 
arrest by blocking CDK1/2 (Kang et al. 2008; Reinhardt and Yaffe 2009). In addition, it 
also influences the stabilisation of stalled forks and origin firing. It was shown in budding 
yeast that mutation of mec1, the budding yeast analogue of ATR, leads to the loss of the 
helicase from the stalled fork thus giving rise to a collapsed replication fork that cannot be 
restarted (Cobb et al. 2003). The mechanisms behind restarting stalled forks are not 
completely understood but it is clear that in order to restart them, they first need to be 
stabilised and this stabilisation seems to be under the control of ATR and Chk1 (Lopes et 
al. 2001; Durkin et al. 2006; Sørensen and Syljuåsen 2012). In addition to fork stabilisation 
and delayed mitotic entry, the intra-S phase checkpoint also inhibits late origin firing and 
slows replication forks that are working on DNA templates that have been damaged 
(Lambert and Carr 2005). 
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1.2.7 Induction of apoptosis 
Apoptosis is a form of cell death chosen by a cell upon intrinsic or extrinsic signals of 
extreme stress or damage beyond repair. As opposed to necrosis, apoptosis is characterised 
by cleavage of a cells components, resulting in fragmentation of the DNA, membrane 
blebbing, chromatin condensation and shrinking of the cell leading to the subsequent 
formation of apoptotic bodies that can be cleared by phagocytic cells without causing a 
spill-over and hence inflammation in the surrounding environment (Kerr et al. 1972).  
There are two major ways to initiate apoptosis, an extrinsic and an intrinsic one. Both lead 
to the activation of caspases (cysteine aspartases), proteases with a cysteine at their active 
centre that cut proteins specifically at sites containing aspartic acid. An active caspase will 
also cleave and activate other caspases, thus increasing the apoptotic signal and reaching a 
point of no return. Many proteins contained in a cell are subject to caspase cleavage, 
including lamins that are essential for the integrity of the nuclear envelope, inhibitor 
proteins for DNA endonucleases, which in turn are released upon degradation of the 
inhibitor and cut the DNA into little pieces and PARP (poly-ADP-ribose-polymerase 1), a 
protein involved in DNA repair that is inactive once cleaved and was, in its cleaved form, 
used in this study as a marker for apoptosis in western blots (Kaufmann et al. 1993). 
The extrinsic apoptotic pathway is triggered when an extracellular molecule, for example 
Tumour necrosis factor alpha or Fas (first apoptotic signal), binds to so-called death 
receptors. Death receptors consist of an extracellular ligand binding site, a transmembrane 
domain and intracellular death domains that recruit initiator procaspases and further 
proteins which can then activate executioner procaspases and spread the death signal 
within in the cell (reviewed in Elmore 2007). 
For this study the intrinsic pathway is of more interest since it can be activated as a 
consequence of replicative stress and DNA damage. Normally there is a balance of pro- 
and anti-apoptotic stimuli within a cell. Upon certain events this balance can be shifted 
towards either end mostly by withdrawal of either pro- or anti-apoptotic factors. Most of 
these factors belong to the Bcl-2 family and are directly or indirectly controlled by p53 
although the exact mechanisms of this regulation are still a matter of debate. However, if 
the balance of these factors is shifted towards the pro-apoptotic ones this always results in 
the permeabilisation of the outer mitochondrial membrane and the release of 
mitochondrial proteins like cytochrome c and others (Kluck et al. 2000; Saelens et al. 2004). 
Cytochrome c binds procaspase 9 and other proteins forming a structure called 
apoptosome (reviewed by Chinnaiyan 1999), leading to the activation of caspase 9 and 
therefore pulling the trigger for programmed cell death. 
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1.3 The G2 specific E3 ligase (G2E3) 
G2E3, as already suggested by its name, belongs to the family of E3 ubiquitin ligases and is 
mainly expressed in G2 and M phase. It was first described in 2001 as a protein with 
maximum expression levels in G2/M and an observed down-regulation after ionizing 
irradiation (Crawford and Piwnica-Worms 2001). As to now, relatively little is known about 
G2E3 but there are strong hints that it is involved in the response to DNA damage and in 
the regulation of apoptosis. In this study we provide evidence that G2E3 plays a role in a 
cell’s response to replicative stress and acts as a regulator of Chk1. 
G2E3 was found to contain a HECT-domain (homologous to E6-associated protein) 
suggesting it might serve as an ubiquitin ligase. However, this HECT domain proved to be 
catalytically inactive but instead seems to control the subcellular localisation of G2E3. 
Nevertheless, G2E3 showed ubiquitin ligase activities in an in vitro assay but this activity 
seems to be mediated by its three PHD/RING-domains (plant homeodomain/really 
interesting new gene) (Brooks et al. 2008). The structure of G2E3 as described by Brooks 
et al. is shown in Figure 4. G2E3 is normally localised in the cell’s nucleus (shown for 
HeLA, Cos-7, SiHa and BSC-40). It was shown that in HeLa cells G2E3 is present in the 
nucleolus and relocates to the nucleoplasm after DNA damage (Brooks et al. 2007). These 
data already suggest that G2E3 could play a role in maintaining genome stability and the 
DDR. But in addition, G2E3 also impacts the induction of apoptosis. It was shown that 
knockout of G2E3 in mice leads to early embryonic lethality mediated by massive 
apoptosis at the blastocyst stage. Heterozygous mice however are phenotypically normal 
and mainly express G2E3 in the central nervous system and limb buds (Brooks et al. 2008). 
Until today it is unclear how exactly these functions are achieved. It is highly likely that 
G2E3 indeed acts as an ubiquitin ligase but its natural substrates remain to be found.  
Ubiquitination in general is a posttranslational modification that often serves as a signal for 
proteasomal degradation but also plays a role in regulating the localisation and activity of 
proteins (Komander and Rape 2012; Swatek and Komander 2016). Ubiquitin is a small 
protein that is covalently bound to a target protein most often by E3 ubiquitin ligases, 
although there are two other protein families known to catalyse this reaction. The ubiquitin 
ligase attaches one (monoubiquitination) to several ubiquitin molecules (polyubiquitination) 
to a target protein thus most often tagging it for proteasomal degradation. The 26S 
proteasome system recognises ubiquitin tagged proteins and subsequently degrades them. 
For example, p53, one of the key factors of the DDR, is normally kept at low levels by 
ubiquitination through its negative regulator Mdm2 and subsequent proteasomal 
degradation. The role of ubiquitin ligases in the development of cancer was reviewed by 
Nakayama and Nakayama in 2006 (Nakayama and Nakayama 2006). In addition to 
proteasomal degradation, ubiquitination is also known to influence chromatin remodelling 
by attaching ubiquitin to histones (Musselman and Kutateladze 2011). Like for example 
phosphorylation, ubiquitination is not an irreversible step. There are several 
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Figure 4: Domain structure of G2E3 
G2E3 consists of three PHD/RING domains that possess in vitro ubiquitin ligase activity 
and are located at the N-terminal half and a HECT domain at the C-terminus that seems to 
control subcellular localisation (Brooks et al. 2007). Also located near the N-terminus are 
three alleged nuclear localisation signals (NLSs), depicted as orange bars. 
1.4 The MAPKAP Kinase MK2 
Mitogen-activated protein kinase-activated protein kinase 2 or short MK2 has for the last 
several years been an emerging research interest regarding its role during such fundamental 
processes like genome maintenance, cell proliferation, cellular stress, gene expression 
regulation and inflammation. MK2 has two structurally related siblings, MK3 and MK5 
that together form the subfamily of MAPK-activated protein kinases. Most importantly for 
this study, MK2 is part of a newly identified non canonical pathway that seems to function 
in parallel to the Chk1 and Chk2 DDR-pathways (Bulavin et al. 2001; Manke et al. 2005; 
Reinhardt et al. 2007). This pathway is activated in response to general stress within a cell, 
including replicative stress. A kinase called p38/MAPK is activated and goes on to 
phosphorylate downstream proteins including p53 and MK2. In its dephosphorylated 
form, MK2 forms a heterodimer together with p38/MAPK within the nucleus. Upon 
phosphorylation, a change in conformation occurs, exposing both the catalytically active 
site and an export signal, leading to MK2’s activation and relocalisation to the cytoplasm 
(Engel et al. 1998; Meng et al. 2002). MK2 itself phosphorylates a wide range of substrates, 
the most notable ones being hsp27 (heat shock protein 27) and Cdc25 phosphatases (see 
1.2.6). Through the inhibition of Cdc25, MK2 activation leads to a cell cycle arrest during S 
phase or at the G2/M boundary. In this respect, MK2 functions similarly to Chk1 and 
Chk2 which is the reason why it is sometimes referred to as Chk3. Interestingly, MK2 also 
shares its minimal phosphorylation motif with Chk1 and Chk2, further supporting the 
theory that it could act as a third checkpoint kinase (Bulavin et al. 2001; Xiao et al. 2006). 
In summary, MK2 is known to be involved in cell-cycle regulation mainly via the intra-S 
phase checkpoint and the G2/M-checkpoint but there are also strong hints that MK2 has 
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further functions in the DNA damage response and replicative stress. This study aims to 
contribute to further understanding these functions. 
1.5 Aims of  this study 
As detailed above, it is known that upon stalling of a replication fork ssDNA is formed 
which leads to the recruitment of various proteins involved in the DNA damage response. 
This study aims to use a new staining method for ssDNA as a read-out for replicative stress 
in order to identify proteins involved in the cellular response to replication fork stalling and 
collapse and to further elucidate their role and regulation. This will on the one hand side 
contribute to our general understanding of a cell’s response to DNA damage and on the 
other hand side help to identify proteins that could in the long run be candidates for 
chemosensitisation, meaning that by inhibiting them with a drug administered to patients 
the effects of chemotherapy on cancer cells could be intensified while simultaneously 
sparing healthy cells from too severe side-effects. In order to achieve these goals, the study 
was subdivided into the following three parts, each one relying on the one before: 
1. Establish the BrdU assay for ssDNA in a large, semi-automated setup as a new method 
to assess replicative stress. 
2. Identify candidates involved in replicative stress via literature search and include them in 
a miniscreen using the BrdU assay for ssDNA. 
3. Pick one or two candidates and investigate their role in replicative stress closer, e.g. find 
out more about their place in the DNA damage response and possible up- and downstream 
regulators and whether they could be candidates for chemosensitisation. 
2 Materials and Methods 13 
2 Materials and Methods 
2.1 Materials 
2.1.1 Buffers and Solutions 
Table 1: Buffers and Solutions 
Blocking solutions 
Western blot 5 % Milk powder in TBST 
Western blot for phospho-antibodies 5 % BSA in TBST 
Immunofluorescence 10 % FCS in PBS 
BrdU Assay for ssDNA 3% BSA, 0.3 % Triton X in PBS 
6x Laemmli buffer 
Tris pH 6.8 0.35 M 
Glycerin 30 % 
SDS 10 % 
Dithiotreitol 9.3 % 
Bromophenol blue 0.02 % 
Cell lysis buffer 
Urea 2 M 
Pefabloc 10 µM 
Pepstatin A 1 µg/ml 
Leupeptin/Aprotinin 1 µg/ml 
dissolved in RIPA 
10x PBS, pH 7.5 
NaCl 239.9 mM 
KCl 2.7 mM 
Na2HPO4 x 2 H2O 8.1 mM 
KH2PO4 1.5 mM 
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1x Pre-extraction buffer, pH 7.5 
Triton X-100 0.5 % 
HEPES 20 mM 
Sucrose 300 mM 
NaCl 50 mM 
MgCl2 x 6 H2O 3 mM 
Ponceau S solution 
Ponceau S 0.5 % 
Glacial acetic acid 1 % 
Ponceau S 0.5 % 
RIPA, pH 7.5 
Triton-X 100 1 % 
Sodium deoxycholate 1 % 
SDS 0.1 % 
NaCl 150 mM 
EDTA 3.722 g 
Tris-HCl pH 7.5 20 mM 
Trasylol 100000 KIE/ l 
SDS-PAGE running buffer 
Tris 25 mM 
Glycin 86.1 mM 
SDS 3.5 mM 
10x TBS, pH 7.4 
Tris-HCl 0.5 M 
NaCl 1.5 M 
1x TBS-T, pH 7.4 
Tween 20 0.1 % 
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Dissolved in 1x TBS 
10x Western salts pH 8.3 
Tris 250 mM 
Glycin 1.92 M 
SDS 0.02 % 
If not explicitly mentioned otherwise, all buffers and solutions are dissolved in H2O. 
2.1.2 Chemotherapeutics and Inhibitors 
Table 2: Chemotherapeutics and Inhibitors 
Name Target Company 
Cisplatin  Cis-Gry, Teva Germany 
Cycloheximide Ribosomes Thermo Scientific 
Gemcitabine  Eli Lilly, Indianapolis, United States 
Hydroxyurea  Sigma Aldrich 
MK III MK2 Calbiochem, Merck 
SB218078 Chk1 Calbiochem, Merck 
UCN-01 Chk1 Sigma-Aldrich 
TRAIL Death-receptors Sigma-Aldrich 
Z-VAD Caspases Sigma-Aldrich 
 
Table 3: Chemicals 
Name Company 
BrdU solution BD Pharmingen 
DMSO AppliChem 
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2.1.3 Kits 
Table 4: Kits 
Name Company 
Click-iT EdU Alexa Fluor High-throughput Imaging assay Invitrogen, Life Technologies 
Immobilion Western HRP Substrate Peroxide Solution Millipore, Merck 
Pierce, BCA Protein Assay Kit Thermo Scientific 
SuperSignal West Femto Maximum Sensitivity Substrate Thermo Scientific 
 
2.1.4 Small interfering RNAs 
Table 5: Small interfering RNAs 
Target ID Type 
control siRNA 1 (scrambled) 4390844 not disclosed 
control siRNA 2 (scrambled) 4390847 not disclosed 
G2E3-A 
s31128 sense 5’GAUGGUAAAUCUACAACAAtt3’ 
antisense 5’UUGUUGUAGAUUUACCAUCtt3’ 
G2E3-B 
s31129 sense 5’GAAGGGUCCUUGUCAAAGAtt3’ 
antisense 5’UCUUUGACAAGGACCCCUUCaa3’ 
G2E3-C 
s31130 sense 5’GGAUGUCUCAGACUUAUAAtt3’ 
antisense 5’UUAUAAGUCUGAGACAUCCaa3’ 
hnRNP-1 s21544  
hnRNP-2 s21545  
p53-1 s605  
p53-2 s607  
p73-1 s14320  
p73-2 s14321  
p73-3 s14321  
All siRNAs are silencer select siRNAs obtained from Ambion/Life Technologies. 
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2.1.5 Antibodies 
Table 6: Primary antibodies used in western blots 
Target Company Cat. No. Organism Dilution 
Chk1 Cell Signaling 2360 mouse 1:1000 
Chk2 Calbiochem CC44 mouse 1:300 
hsc-70 Santa Cruz sc-7298 rabbit 1:15000 
hsp27 pS82 Cell Signaling 2401 rabbit 1:1000 
MK2 pT334 Cell Signaling 3007 rabbit 1:1000 
p21 Calbiochem Op64 mouse 1:200 
p53 Santa Cruz sc-126 mouse 1:1000 
phospho-Chk1 (S317) Cell Signaling 2344 rabbit 1:1000 
phospho-Chk2 (T68) Cell Signaling 2661 rabbit 1:1000 
γ-H2AX pS139 Millipore 05-636 mouse 1:4000 
All primary antibodies for western blots are diluted in western blot blocking solution (5% 
milk powder), antibodies targeting phosphorylated Chk1 or phosphorylated Chk2 are 
diluted in western blot blocking solution for phospho-antibodies (5% BSA). 
Table 7: Primary antibodies used in immunofluorescence 






BrdU Abcam #Ab 8039 mouse different 
BrdU ABD Serotec MCA260 rat different 
γ-H2AX pS139 Millipore 05-636 mouse 1:2000 
γ-H2AX pS139 Cell Signaling #20E3 rat 1:1000 
The γ-H2AX antibody is diluted in normal IF blocking solution (5% FCS), the BrdU 
antibody, used in the BrdU assay for ssDNA is diluted in 3 % BSA in PBS. 
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Table 8: Secondary antibodies used in western blots 
Target Company Cat. No. Dilution 
HRP-coupled AffiniPure 











All Secondary antibodies for western blots are diluted in western blot blocking solution 
(5% milk powder), if the primary antibody targets a phosphorylated structure (e.g. 
phospho-Chk1 or phospho-Chk1), secondary antibodies are diluted in western blot 
blocking solution for phospho-antibodies (5% BSA). 
Table 9: Secondary antibodies used in immunofluorescence 
Target Company Cat. No. Dilution 




















All secondary antibodies for immunofluorescence are diluted in IF blocking solution (5% 
FCS). 
2.1.6 Cell culture 
Table 10: Cell lines 
Cell line Origin Cultured in 
U2OS human osteosarcoma DMEM 
HCT116 p53 +/+  human colon carcinoma McCoy’s Medium 
HCT116 p53 -/- 
human colon carcinoma, p53 
deficient 
McCoy’s Medium 
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If not explicitly mentioned otherwise, all cell lines are cultured in media with supplements. 
Table 11: Media for cell culture 
Dulbecco’s Modified Eagle’s Medium (DMEM) 
DMEM powder 10 g/l 
NaHCO3 3.7 g/l 
HEPES 5,96 g/l 
DMEM with supplements 
DMEM  
FCS 10 % 
Penicillin/Streptomycin 50 U/ml 
L-Glutamine 200 µM  
Ciprofloxacin 10 µg/ml 
Tetracycline 2 µg/ml 
McCoy’s Medium with supplements 
McCoy’s Medium  
FCS 10 % 
Penicillin/Streptomycin 50 U/l 
L-Glutamine 200 µM 
All reagents are dissolved in H2O. 
2.2 Methods 
2.2.1 Human cell culture 
Human cell lines were used for all experiments, for a list of all cell lines, see Table 10. The 
cells were cultured at 37 °C under 5 % CO2 in Dulbecco’s Modified Eagle Medium 
(DMEM), or McCoy’s Medium, both with supplements (see Table 11). All cell culture work 
was carried out under sterile conditions and with pre-warmed (37 °C) media and reagents. 
Cells were split approximately three times per week with dilutions between 1:2 and 1:10 
depending on the cell line and density of cells. For splitting and experimental use, cells 
were washed with PBS and detached from their dish by incubating them with 0.1% 
Trypsin/EDTA for a couple of minutes at 37 °C. In order to stop the enzymatic activity of 
trypsin, cell culture medium with FCS was added and the cells were diluted and reseeded. 
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For experimental use, cells were seeded onto 6-, 12- or 96 well plates with a fixed amount 
of cells per well. To achieve this, cells were counted in a Neubauer counting chamber and 
diluted accordingly. 
2.2.1.1 Transient transfection with siRNAs 
In order to perform a selective knockdown of target proteins, such as G2E3, cells were 
transiently reverse transfected with siRNAs. As a transfection reagent, Lipofectamine 2000 
was used and the final concentration of siRNA was 10 nM. For preparation of the 
transfection reagent, the required amount of Lipofectamine 2000 (see Table 12) was added 
to medium without supplements, vortexed and incubated for 5 min at room temperature. 
For U2OS, DMEM was used and for HCT116 McCoy’s Medium. In parallel, a suitable 
amount of siRNA (see Table 12) was also diluted in medium without supplements and 
vortexed. These two solutions were hereafter combined, gently mixed and left to incubate 
for 20 min at room temperature. This mix was then given into the wells of a cell culture 
plate and a fixed amount of cells in medium with supplements was added. The plates were 
incubated for 24 h at 37 °C before the medium was first changed. A list of all siRNAs that 
were used in this work can be found in Table 5. 
Table 12: Preparation of transfection mix and cell numbers for transient transfection with 
siRNAs 
96 well plates 
Cell number U2OS 8000 
siRNA mix 25 µl medium + 1.5 pmol siRNA 
Transfection mix 14.75 µl medium + 0.25 µl LF2000 
12 well plates 
Cell number U2OS 100000 
Cell number HCT116 180000 
siRNA mix 67.5 µl medium + 15 pmol siRNA 
Transfection mix 28.65 µl medium + 1.35 µl LF2000 
6 well plates 
Cell number U2OS 160000 – 22000 depending on the experiment 
Cell number HCT116 360000 
siRNA mix 135 µl medium + 30 pmol siRNA 
Transfection mix 57.3 µl medium + 2.7 µl LF2000 
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2.2.1.2 Treating cells with chemotherapeutics or other chemicals 
All drugs were pre-dissolved in their respective solvent and then added to pre-warmed cell 
culture medium. Controls were treated with an equivalent amount of DMSO or H2O. If 
different amounts of DMSO or Ethanol had to be used for different inhibitors in one 
experiment, controls and all other treatments were adjusted to also contain the highest 
DMSO or Ethanol concentration. 
Table 13: Concentrations of drugs and chemicals for cell treatment 
Chemical or drug Concentration Solvent 
Chk1 Inh. UCN-01 300 nM DMSO 
Chk1 Inh. SB218078 5 µM DMSO 
Cycloheximide 5 µg/ml Ethanol 
Gemcitabine  different H2O 
Hydroxyurea 2 mM H2O 
MK2 Inh 10 µM DMSO 
TRAIL 75 ng/ml Ethanol 
Z-VAD 50 µM DMSO 
 
2.2.1.3 Generation of cell lysates for SDS-PAGE 
To prepare cell lysates for SDS polyacrylamide gel electrophoresis (SDS-PAGE), cells were 
grown and treated in 12 well plates and scraped off. The scraping as well as all other steps 
were performed on ice to hinder the degradation of proteins. After scraping the cells off in 
their medium, they were collected and centrifuged for 5 min at 845 g. The resulting pellet 
was washed with PBS, centrifuged again for 5 min at 845 g and then lysed in cell lysis 
buffer (see Table 1). The Pierce® BCA Protein Assay Kit was used to determine and then 
adjust the protein concentration of all samples to equal amounts by diluting them with 
RIPA buffer. These samples were then either stored at -80 °C or directly used for SDS-
PAGE by adding 6x Laemmli buffer, and boiling them for 5 min at 95 °C while shaking at 
1400 rpm. Before loading them onto the gel, samples were shaken with 1400 rpm for 30 
min at 4 °C to shear the DNA. 
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2.2.2 Western blot 
2.2.2.1 SDS-PAGE 
SDS-PAGE is a method to separate proteins by their molecular weight and mobility in an 
electrophoretic field using a polyacrylamide gel. It was developed and first described by 
Laemmli (Laemmli 1970). The protein-samples are denatured in the presence of Laemmli 
buffer that contains sodium dodecyl sulphate (SDS) which is a detergent and binds to the 
proteins in a stoichiometric way. This leads to the proteins being negatively charged 
proportionally to their molecular weight. If an electric field is now applied to the gel 
containing the proteins, they will travel towards the anode with larger proteins moving 
more slowly through the pores of the resolving gel and smaller proteins moving faster. For 
SDS-PAGE the gel is composed of two parts, the stacking gel and the resolving gel. The 
stacking gel is used to focus the samples. Therefore, it contains only 5 % Polyacrylamide at 
a pH of 6.8. The running buffer contains chloride and glycine ions with the chloride being 
charged negatively due to the low pH in the stacking gel and the glycine being a zwitterion. 
Between these two fronts of ions, a partial electrical field is generated in which the original 
sample is situated and therefore focused by being repelled by both negatively charged 
fronts. The sample then enters the resolving gel, which was cast using 12 % or 15 % 
polyacrylamide and buffered to a pH of 8.8. Under these conditions glycine is now 
deprotonated and moves faster than the protein sample itself, therefore no partial electric 
field is generated anymore and the sample separates according to the molecular weight of 
the different proteins. The exact composition of the gels can be found in Table 14. The 
resolving gel was cast first in a glass chamber and covered with isopropanol to achieve an 
even surface. The isopropanol was removed after polymerisation, the stacking gel was cast 
on top of the resolving gel and a comb was inserted. 
Table 14: Gels for SDS-PAGE 
Reagent 5 % stacking gel 12 % resolving gel 15 % resolving gel 
Acrylamide-
bisacrylamide 
5% 12% 15% 
Tris, pH 6.8 (1 M) 126 mM - - 
Tris, pH 8.8 (1.5 M) - 375 mM 375 mM 
SDS 0.1 % 0.1 % 0.1 % 
APS 0.1 % 0.1 % 0.1 % 
TEMED 0.3 % 0.4 % 0.4 % 
Dissolved in H2O 
The prepared cell lysates (see 2.2.1.3) were loaded onto the gel, in the first pocket of each 
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gel a pre-stained protein ladder was loaded. Gels were run at 80 V for the stacking gel and 
130 V for the resolving gel in SDS running buffer (see Table 1).  
2.2.2.2 Immunoblotting and immunostaining 
Immunoblotting or western blotting is a method that allows assessment of protein levels 
and post-translational modifications such as phosphorylation (Renart et al. 1979; Towbin et 
al. 1979). The method allows a transfer of the proteins from the gel onto a membrane 
where they can be detected by an antibody directed against a surface epitope. A secondary 
antibody, which is coupled to horseradish peroxidase (HRP), is directed against the first 
antibody’s constant region. By applying luminol, the oxidisation of the substrate can be 
detected by measuring luminescence.  
After the protein samples were separated by SDS-PAGE, the samples were transferred 
onto a nitrocellulose membrane by wet electroblotting (Bittner et al. 1980). In order to do 
so, the gel was put into a stack with two sponges and three Whatman papers on the 
cathode side, followed by the gel, the nitrocellulose membrane, three Whatman papers and 
a sponge on the anode side. This stack was placed in a plastic holder and put into a blotting 
chamber that was subsequently filled up with blotting buffer (see Table 1). An electric field 
with 90 V for 90 min at 4 °C was applied to achieve the transfer. As a quality control and 
to verify the equal transfer of proteins, membranes were stained with Ponceau S solution 
prior to staining them with antibodies. The membrane was then blocked in 5% milk or in 
the case of phospho-antibodies in 5% BSA (see Table 1) for 1 h and subsequently 
incubated with respective antibodies dissolved in milk or BSA for 2 h at room temperature 
or overnight at 4 °C. All primary antibodies used in western blots are listed in Table 6. 
Afterwards, the membrane was washed in TBST three times for 5 min. The secondary 
antibody in blocking solution was added for 1 h, followed again by three times washing in 
TBST. To visualize the bands Immobilion Western HRP Substrate Peroxide Solution (Millipore) 
or SuperSignal West Femto Maximum Sensitivity Substrate (Pierce) was added, followed by the 
detection of luminescence using the Intas ChemoStar Imager Software. 
2.2.3 High content immunofluorescence microscopy 
Immunofluorescence makes it possible to visualize proteins by targeting them with 
fluorophores coupled to antibodies. As in immunostaining, a primary antibody, directed 
against the protein of interest, is used together with a secondary antibody targeting the 
first’s constant region. This secondary antibody carries a fluorescent dye. Upon excitation, 
the emitted fluorescence can be detected using a fluorescence microscope. Using different 
fluorophores, emitting different wavelengths, makes it possible to stain more than one 
protein per sample.  
In this study, phosphorylation of H2AX was measured by high content 
immunofluorescence microscopy. For this purpose, 96 well plates were used to grow the 
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cells and each treatment was carried out in triplicates. For staining, the medium was 
removed and the cells were fixed with 4% Paraformaldehyd dissolved in PBS for 20 min at 
room temperature, rinsed twice in PBS and permeabilised with 0.5% Triton-X dissolved in 
PBS for 10 min at room temperature. After rinsing them again four times in PBS, blocking 
solution (10 % FCS) was added for 10 minutes. Hereafter, the cells were stained with the 
primary antibody, dissolved in blocking solution, for 1 h at room temperature or overnight 
at 4 °C. The primary antibody was then removed, the cells washed again three times with 
PBS and the secondary antibody was added and left to incubate for 45 min at room 
temperature. Together with the secondary antibody, 0.5 µg/ml Hoechst 33342 (Molecular 
Probes, Cat. No. H3570) were added to stain the cell nuclei. Afterwards, the cells were 
washed twice with PBS and either directly used for fluorescence microscopy or stored at 
4 °C. All work involving the secondary antibody was, as far as possible, carried out in the 
dark to protect the fluorophores from light. A list of primary and secondary antibodies can 
be found in Table 7 and Table 9. Per well, nine microscopic pictures with a 10x 
magnification were taken automatically using the BD pathway 855 system. With the 
AttoVision software, regions of interest (ROI) were defined by using the Hoechst channel 
as a mask. Since Hoechst selectively stains DNA (Latt et al. 1975) the ROIs contained only 
cell nuclei. Within these ROIs the nuclear fluorescence intensity of the γ-H2AX channel 
was quantified and a mean value per well was calculated. The data were further processed 
using R: A language and environment for statistical computing, Microsoft Access and GraphPad Prism 
version 5 and 7, GraphPad Software, San Diego California USA. 
2.2.4 BrdU assay for ssDNA 
The BrdU assay for single stranded DNA was employed to assess the amount of single 
stranded DNA per cell. The method was modified, based on a protocol published by 
Syljuåsen and colleagues (Syljuåsen et al. 2005). Our group published this modified 
protocol in 2013 (Köpper et al. 2013). Cells were exposed to 10 µM BrdU for 24 h prior to 
treatment; the treatment was then carried out under continued presence of BrdU. BrdU is 
incorporated during replication into the DNA double strand instead of thymidine. 
Normally, BrdU labelling is used to look at replicational activity of cells. In order to make 
the BrdU accessible for an antibody, the DNA double strand is normally broken down into 
single strands by the opening of chromatin using for example HCl, leading to a BrdU signal 
at all incorporation sites. Opposed to this, the BrdU assay for ssDNA only detects the 
BrdU at sites where the DNA itself formed single strands during the carried out treatment. 
To this end, no denaturation or opening of chromatin was done at any point during the 
staining procedure. Therefore, the antibody can only recognise the BrdU at sites of ssDNA 
that occur naturally for example at stalled replication forks. Therefore the BrdU assay 
provides additional information about the amount and specific kind of DNA damage that 
accumulated during the treatment. This can be combined with a parallel staining for 
γH2AX. 
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For use in the BrdU assay, two different workflows were established. Cells were either 
grown on coverslips in a 6 well plate for use with a confocal microscope or in 96 well 
plates for high content immunofluorescence microscopy. The staining procedure is similar 
for both. All steps were carried out on ice. After removal of the medium, cells were pre-
extracted with cold (4 °C) pre-extraction buffer (see Table 1) for 5 min. They were then 
rinsed twice in PBS and fixed with 4 % formaldehyde in PBS for 10 min. After washing 
them again two times in PBS, the samples were blocked and permeabilised with 3 % BSA 
and 0.3 % Triton X in PBS for 30 min. The BrdU antibody was then diluted in 3 % BSA in 
PBS and added for 1 h at room temperature or overnight at 4 °C. Afterwards, cells were 
washed twice in PBS again and incubated with the secondary antibodies dissolved in 3 % 
BSA in PBS for 1 h at room temperature followed by washing them three times and using 
them either for confocal microscopy or high content immunofluorescence microscopy. For 
cells grown on cover slips, the cover slips were transferred into a wet-chamber after 
fixation and stained therein. After the staining was completed, they were briefly dried and 
mounted with DAPI on glass slides by placing the cover slips face down on 4 µl drops of 
DAPI mounting medium. Excessive mounting medium was then removed and the cover 
slips fixed with nail polish. A Zeiss Confocal LSM 510 meta microscope was used to obtain 
pictures of the cells. Fiji was used for further image processing. For cells grown in 96 well 
plates, 0.5 µg/ml Hoechst 33342 were added together with the secondary antibody. The 
plates were used for high content immunofluorescence microscopy as described above. 
Again the Hoechst channel was used to define ROIs wherein the BrdU signal was then 
quantified. 
2.2.5 Statistical analysis 
Statistical analysis was done in Microsoft Excel and GraphPad Prism version 5 and 7. To test 
whether the difference between two groups was significant, an unpaired two-tailed 
student’s t-test was used. Variances were assessed using an F-Test, if needed variances were 
corrected using Welch’s correction. Differences between two sets of data were considered 
statistically significant if p<0.05. In figures asterisks indicate the following levels of 
significance: * p<0.05, ** p<0.01, *** p<0.001. 
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3.1 The BrdU assay detects ssDNA 
In order to use ssDNA as a read-out for replicative stress, a method to reliably detect it 
needed to be established. Therefore, a pre-existing method (Syljuåsen et al. 2005) was 
modified as described in the Materials and Methods part of this thesis (2.2.4). The 
underlying principle of the staining procedure is depicted in Figure 5. Furthermore, Figure 
6 shows a comparison between the newly established BrdU assay for ssDNA and the 
routine method of using BrdU incorporation for an assessment of replicational activity. 
The Chk1 inhibitor UCN-01 was used as a positive control. UCN-01 was also used by 
Syljuåsen et al. and leads to a reliable, high signal in U2OS and HCT116 cells. Treatment 
with hydroxyurea for 4 h can also be used as a positive control (see Figure 7 and Figure 8). 
For the antibody test, staining with only the secondary antibody was used as a negative 
control, for all other experiments cells that were not treated with BrdU were employed as a 
negative control. 
 
Figure 5: Schematic depiction of the BrdU assay for ssDNA 
(A) During normal replication, helicase unwinds the DNA creating a replication fork, the 
leading strand is replicated continuously from 5’ to 3’, the lagging strand’s replication is 
uncontinuously with Okazaki fragments being generated and later fused together. (B) Upon 
DNA damage, as indicated by the bolt, the DNA polymerase may stop replicating the 
DNA but the helicase continues unwinding it leading to the exposure of ssDNA which is 
then accessible for an antibody; in order to label the cells with BrdU they were incubated 
with 10 µM BrdU for 24 h prior to treatment, so the BrdU is incorporated in the S phase 
preceding the one during which the treatment is carried out; the BrdU is then detected by 
an antibody; detection is only possible if the DNA is single stranded e.g. at a stalled or 
collapsed replication fork. 
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Figure 6: Comparison between BrdU assay for ssDNA and BrdU incorporation for 
replicational activity 
(A) BrdU is incorporated into the DNA one S Phase prior to treatment; cells are incubated 
with 10 µM BrdU for 24 h; afterwards, the treatment is carried out under continued 
presence of BrdU; a pre-extraction is done during the fixation and no denaturation of the 
DNA is carried out, leaving only ssDNA accessible for an antibody. (B) Labelling with 
BrdU and treatment are done simultaneously to assess how the treatment interferes with 
replicational activity; after fixation the DNA is denatured to make all the BrdU accessible 
for an antibody. 
3.1.1 Only one antibody to BrdU reliably detects its epitope upon replicative 
stress in a high-content semi-automated setup 
Different antibodies were tested for use in the BrdU assay for ssDNA. The aim was to find 
an antibody that reliably detects the BrdU, can be used for costaining with γ-H2AX and 
works well in the automated microscopy setting. Three different antibodies were tested, 
two of them have a mouse constant region, one a rat constant region. For γ-H2AX there 
were already two antibodies that work very well, one derived from rat and one from mouse 
so that the desired costaining with γ-H2AX is possible by using the one with the respective 
other constant region. For use with the BD pathway system for high-content 
immunofluorescence, the staining needs to be very homogenous in terms of background 
signal and maximum signal per well so that the same exposure time can be used for all 96 
wells on the plate in order to afterwards quantify and compare the fluorescence intensities 
within the different wells. It can be seen in Figure 7 that not all of the tested antibodies are 
suitable for the BrdU assay for ssDNA. #Ab 8039 produces a very high background signal 
since the specific signal within the nucleus is so weak that the exposure time during which 
the fluorescence dye is excited needed to be set to 0.77 s in the 1:100 dilution. For 
comparison, the final antibody RPN 20AB (Figure 8) needs an exposure time of 0.2 s for 
the 1:300 dilution. Another tested antibody, MCA260 also shows a weak staining within the 
nucleus, background signal in the cytoplasm and precipitates. These aggregates of antibody 
lead to a very high maximum signal intensity which makes it complicated to find the right 
exposure time for the much weaker fluorescence signal emitted by the antibodies bound 
within the cells’ nuclei. Only the RPN 20AB exhibits a specific signal within the nucleus 
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with no high background (see Figure 8). As a result, it was decided to use the RPN 20AB in 
a dilution of 1:300 from here on. 
 
Figure 7: Not all BrdU antibodies can be used in the BrdU assay for ssDNA 
Two different antibodies were tested with the established workflow for the BrdU assay for 
ssDNA; after incubating U2OS-cells with 10 µM BrdU for 24 h, cells were treated with 
2mM hydroxyurea for 4 h under continued presence of BrdU, blue is the Hoechst signal, 
green the BrdU signal for ssDNA; (A) #Ab 8039 – detection of a specific BrdU signal 
within the nucleus only in a dilution of 1:50, higher dilutions preclude BrdU detection and 
overexposure only allows for the detection of a non-specific signal. (B) MCA260 – no 
specific BrdU signal can be detected as can be seen in the comparison between the samples 
stained with the primary antibody and the sample stained only with the secondary antibody; 
the antibody aggregates and forms precipitates, thereby impeding the setting of the right 
exposure time within the automated microscopy workflow. (A+B) pictures with 10x 
magnification, obtained using the BD pathway system 
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Figure 8: Staining with RPN 20AB produces a specific and selective signal within the 
nucleus 
(A) Good staining for BrdU could be achieved at all tested dilutions; U2OS cells were 
labelled with 10 µM BrdU for 24 h and treated with 1 µM gemcitabine for 4 h, blue: 
Hoechst, green: BrdU signal for ssDNA; pictures with 10 x magnification, obtained using 
the BD pathway system. (B) Staining occurs selectively and with a high spatial resolution 
within the nucleus; an exemplary picture of U2OS cells treated with hydroxyurea for 4 h 
after labelling them with 10 µM BrdU for 24 h, blue: DAPI, green: BrdU signal for ssDNA; 
picture with 63x magnification, obtained using a Zeiss Confocal LSM 510 meta microscope 
3.1.2 ssDNA is not mainly generated as a result of increased apoptosis 
The aim of this study is to use the accumulation of ssDNA as a readout for replicative 
stress occurring in tumour cells and to apply this method, once established, to gain more 
knowledge about different enzymes known or suspected to be involved in replicative stress 
and the DNA damage response. However, following DNA damage, tumour cells can also 
undergo apoptosis if damage is too severe to be repaired by the cell’s repair mechanisms. 
Therefore, it was necessary to make sure that the accumulation of ssDNA observed with 
the BrdU assay is really a function of replicative stress and not mainly due to the release of 
endonucelases during apoptosis (Zhang and Xu 2000). To achieve this, cells were 
intentionally driven towards apoptosis and stained for ssDNA. For the initiation of 
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apoptosis, cells were incubated with TRAIL or TRAIL in combination with 
Cycloheximide. TRAIL binds to the death receptors of a cell thereby inducing programmed 
cell death (Wiley et al. 1995). Cycloheximide inhibits protein biosynthesis, providing an 
additional stimulus for apoptosis. Figure 9 depicts the results of these experiments. A 1.2 
fold increase in BrdU intensity for cells treated with TRAIL compared to the control and a 
1.3 fold increase for cells treated with TRAIL and Cycloheximide can be observed. 
Regarding γ-H2AX intensities, the data show a very slight (1.09 fold) increase after 
treatment with TRAIL and a 1.7 fold increase after treatment with TRAIL and 
Cycloheximide. This leads to the conclusion that although some ssDNA seems to be 
generated when a cell induces apoptosis the main amount of ssDNA does not accumulate 
via this pathway. Hence the BrdU assay is suitable to provide an additional read-out for 
replicative stress and is not significantly confounded via apoptosis. 
 
Figure 9: An increased signal for ssDNA in the BrdU assay and for γ-H2AX in 
immunofluorescence is not mainly mediated via apoptosis 
U2OS cells were treated with 75 ng/ml TRAIL, 75 ng/ml TRAIL and 5 µg/ml 
Cycloheximide (CHX) or Ethanol as a negative control for 5.5 h (A, B). Only a slight 
induction of BrdU-signal as a read-out for ssDNA or γ-H2AX-signal upon apoptosis can 
be detected; Boxplots show the median, 25th and 75th percentile, whiskers indicate 5th and 
95th percentile (C). As a control for the induction of programmed cell death, the number of 
ROIs, corresponding to the number of nuclei, is shown; indicated are mean value and 
SEM. 
3.1.3 The BrdU signal correlates with γ-H2AX  
Upon DNA damage the histone-variant H2AX is phosphorylated on Serine 139 by ATM, 
ATR and DNA-PK (Burma et al. 2001) and then called γ-H2AX (see also 1.2.4). As          
γ-H2AX is an established hallmark of the DNA damage response (Stucki and Jackson 
2006) and also occurs after the exposure of ssDNA (Kinner et al. 2008) it is a good 
validation of the BrdU assay for ssDNA to test whether the BrdU signal correlates with the    
γ-H2AX signal. Indeed, there is a high correlation between the BrdU signal for ssDNA and 
γ-H2AX as can be seen in Figure 10. In addition, it was previously shown that the signal 
generated by the BrdU assay also colocalises with RPA that is recruited to stretches of 
ssDNA (Syljuåsen et al. 2005). 
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In summary, all the data show that the BrdU assay for ssDNA provides a reliable read-out 
for replicative stress that is not mediated via apoptosis and correlates with well established 
other markers of the DNA damage response. It was concluded that the BrdU assay for 
ssDNA is a useful tool to shed more light on the accumulation of ssDNA and its 
regulation after DNA damage. 
 
Figure 10: Accumulation of ssDNA correlates with phosphorylation of H2AX 
BrdU labelled U2OS cells were used for the BrdU assay for ssDNA and simultaneously 
stained for γ-H2AX; fluorescence intensity of γ-H2AX is plotted against the respective 
BrdU intensity of the same ROI; the correlation coefficient r is given. (A) Cells were 
treated with hydroxyurea for 4 h after labelling them, r= 0.8699, p <0.001. (B) Cells were 
treated with Chk1 inhibitor UCN-01 for 4 h after labelling, r = 0.8704, p <0.001. 
3.2 The ubiquitin ligase G2E3 plays a role in replicative stress 
The intent of this study is to identify possible targets for chemosensitisation by using the 
accumulation of ssDNA as a read-out and to gain more insight in the mechanisms involved 
in replicative stress and mainly the generation of ssDNA. Therefore, the BrdU assay 
together with a costaining for γ-H2AX was employed for a mini-screen, which included 
proteins known to be involved in the DNA damage response and replicative stress. 
Gemcitabine was used to induce DNA damage as it is incorporated into the nascent DNA 
strand, leading to replication fork stalling and replicative stress (see 1.1.2.1). The proteins 
included were p53 as one of the most essential tumour suppressor genes, its homologue 
p73 (see 1.2.3), the Ubiquitin Ligase G2E3 (see 1.3) and hnRNP A.0, a member of the 
hnRNP A/B subfamily (Myer and Steitz 1995) which is known to be involved in the 
binding of pre m-RNA and found to induce γ-H2AX in a genome-wide siRNA screen 
(Paulsen et al. 2009). The results of this mini-screen are shown in Figure 11. Interestingly 
the knockdown of p53 or p73 did not lead to a relevant induction of ssDNA. The used 
siRNAs for p73 knock down all isoforms of p73 including the one lacking the 
transactivation domain. It would therefore be possible that by knocking down all p73 
isoforms regardless of their activity, more promoters are freed and hence could lead to an 
induction of p53, which would be able to rescue the initial effects that may have been there 
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from the p73 knockdown. To exclude this possibility a double knockdown of p53 and p73 
was performed which, although statistically significant showed just a slight additional 
accumulation of ssDNA, see Figure 12. This suggests that the accumulation of ssDNA 
mainly occurs in a p53 and p73 independent manner. For hnRNP the results were 
inconclusive between the two siRNAs used and therefore interpreted as most likely being 
off-target effects. Opposed to this, the knockdown of G2E3 led to a strong induction of 
ssDNA and this effect was consistent between two different siRNAs with a 4.02 fold 
increase for siRNA G2E3 A and a 3.84 fold increase for siRNA G2E3 C. G2E3 was 
heretofore investigated in our group in terms of its role during apoptosis, cell proliferation 
and the DDR upon cisplatin-treatment. As a result of the mini-screen G2E3 was identified 
as a potential regulator of stalled replication forks and single strand breaks which can lead 
to the exposure of ssDNA. 
 
Figure 11: Knockdown of G2E3 shows the strongest ssDNA-induction of all tested DDR 
components 
To identify components of the DNA damage response that influence the formation of 
ssDNA, a mini-screen in U2OS cells including p53, p73, hnRNP A and G2E3 was 
performed, each protein was targeted by at least two different siRNAs to minimise off-
target effects, cells were labelled with 10 µM BrdU for 24 h and treated with either 300 nM 
gemcitabine for 24 h under continued presence of BrdU (A) or H2O as a negative control 
(B). Boxplots show the median, 25th and 75th percentile, whiskers indicate 5th and 95th 
percentile. (A+B): A baseline increase of 2.01 fold after 24 h gemcitabine treatment for the 
siRNA Control (Ctrl 2) is observed and a 4.02 fold increase after 24 h gemcitabine for 
G2E3 knockdown with G2E3 A and 3.84 fold increase after 24 h gemcitabine for G2E3 
knockdown with G2E3 C. 
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Figure 12: Double knockdown of p53 and p73 does not lead to an increase in ssDNA 
In U2OS cells a knockdown of p53, p73 and a double-knockdown of both proteins was 
performed, followed by labelling the cells with BrdU for 24 h and treating them with       
300 nM gemcitabine for further 24 h under continued BrdU presence. The Chk1 inhibitor 
UCN-01 was included as a positive control; boxplots show the median, 25th and 75th 
percentile, whiskers indicate 5th and 95th percentile. Neither knockdown of p53 nor p73 
leads to a significant induction of ssDNA. Double-knockdown of p53 and p73 leads to a 
very slight, although statistically significant 1.13 fold increase of ssDNA as opposed to the 
gemcitabine treated control. 
3.2.1 Knockdown of G2E3 leads to an accumulation of ssDNA  
As found in the mini-screen knockdown of G2E3 leads to an increased signal in the BrdU 
assay. This finding was consistent and reproducible throughout a series of experiments. To 
further clarify at which stage of DNA damage the ssDNA was generated the temporal 
resolution of the observed phenomenon needed to be determined. To do so, cells in which 
G2E3 was temporarily knocked down via siRNA were treated with gemcitabine for only 4 
h in addition for the previously used 24 h. Strikingly after 4 h gemcitabine treatment, this 
led to the reduction of γ-H2AX and only a very slight increase in ssDNA. The data is 
shown in Figure 13. 
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Figure 13: Gemcitabine induces strong induction of ssDNA and γ-H2AX in G2E3 
knockdown cells after 24 h but only a slight, non-significant increase in ssDNA and even a 
reduction of γ-H2AX after 4 h 
U2OS cells were transfected with two different siRNAs against G2E3 and treated with 300 
nM gemcitabine for 24 h or 1 µM gemcitabine for 4 h after labelling them with 10 µM 
BrdU for 24 h; boxplots show the median, 25th and 75th percentile, whiskers indicate 5th and 
95th percentile. After 24 h both siRNAs targeting G2E3 lead to a highly significant 
induction of ssDNA as observed in the BrdU assay as well as an induction of γ-H2AX. 
After 4 hours of gemcitabine treatment with a high dose, no significant change in the 
amount of ssDNA is detected although the data clearly show that some cells seem to 
accumulate a high degree of ssDNA as expressed by the increased outliers and high 
fluorescence intensities after G2E3 knockdown; for γ-H2AX treatment with a high dose of 
gemcitabine even leads to a highly significant reduction of γ-H2AX. 
A possible explanation for the increase in ssDNA and γ-H2AX after 24 h but the decrease 
after 4 h could be that the knockdown of G2E3 together with gemcitabine treatment 
induces apoptosis. If this were true, G2E3 knockdown could first prevent an adequate 
response to DNA damage generated by gemcitabine and indicated by the decrease in 
ssDNA and γ-H2AX after 4 h but then lead to such a high amount of unaddressed damage 
that the cell induces apoptosis within 24 h thusly leading to an increase in ssDNA and      
γ-H2AX. Although normally ssDNA is not generated as a result of apoptosis (see 3.1.2) 
this could still be true for γ-H2AX and could also not generally be excluded for ssDNA in 
cells with knocked down G2E3. To clarify this, an experiment was conducted during which 
cells with knocked down G2E3 were treated with gemcitabine and Z-VAD an inhibitor of 
caspases to prevent apoptosis. No difference between the cells treated with Z-VAD and 
the control was found. Therefore, it was concluded that the decrease is not due to 
apoptosis.  
3 Results 35 
 
Figure 14: G2E3 knockdown in combination with gemcitabine treatment induces ssDNA 
and γ-H2AX independent of apoptosis 
U2OS cells were transiently transfected with siRNA against G2E3, labelled with 10 µm 
BrdU for 24 h and treated with 300 nM gemcitabine for 24 h and either 50 µM Z-VAD or 
DMSO as control under continued presence of BrdU; after fixation, cells were processed 
for use in the BrdU assay for ssDNA and co-stained for γ-H2AX; boxplots show the 
median, 25th and 75th percentile, whiskers indicate 5th and 95th percentile. There is no 
significant difference in either ssDNA accumulation or γ-H2AX levels if apoptosis is 
inhibited via Z-VAD. The numbers of ROIs are included as a control and show that upon 
Z-VAD treatment indeed apoptosis seems to be inhibited as more cells survived treatment. 
3.2.2 Knockdown of G2E3 decreases levels of phosphorylated Chk1 
Having found out that G2E3 plays a role in replicative stress and impacts the accumulation 
of ssDNA as well as the generation of γ-H2AX the question arose whether this could be 
due to a process occurring in direct proximity to the replicating strand of DNA. It was 
therefore investigated whether G2E3 also influences the signalling cascade known as the 
DNA damage response and if so at which point during the cascade does this interference 
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occur? To this end, a series of western blot experiments were conducted to assess protein 
levels of key players involved in the DDR. As a cellular system U2OS cells were used to 
start with, since they are well established in cancer research and have been used for all 
previous BrdU assay experiments during this study. Another treatment duration of 6 h in 
addition to the normally used 24 h was included because preliminary work in our lab 
showed the strongest pChk1 signal upon gemcitabine treatment to occur after 5 – 6 h. The 
results of these experiments can be found in Figure 15. In the control cells, treatment with 
gemcitabine induces phosphorylation of Chk1 to pChk1 after 6 h and 24 h with no 
apparent difference regarding the signal intensity between these two time points. An 
induction of p53 can also be observed as well as a signal increase for γ-H2AX after 24 h. 
For both samples in which two different siRNAs were used to knockdown G2E3 there is a 
reduction in phosphorylated Chk1 after 6 h and 24 h gemcitabine treatment which is 
especially strong after 6 h, suggesting that G2E3 is not only involved in the early response 
to DNA damage but also directly or indirectly regulates the phosphorylation and hence 
activation of Chk1 one of the most important regulators of the DDR after single-strand 
breaks. Furthermore the western blots confirmed previous findings from 
immunofluorescence that knockdown of G2E3 leads to an increase in γ-H2AX after 
gemcitabine treatment. Previous experiments in our lab showed that G2E3 negatively 
regulates p53 (Schmidt et al. 2015). This leads to the question if G2E3’s effect on pChk1 
could somehow be mediated or influenced via p53. Consequently the immunoblot 
experiments were repeated in a system well suited to answer this question: a colorectal 
cancer cell line that exists in two forms, one possessing two copies of p53 (HCT116 
p53+/+) and one possessing none of them (HCT116 p53-/-). The results of these 
experiments are again depicted in Figure 15. In both cell lines, the transient knockdown of 
G2E3 leads to a reduction of pChk1 after 6 h and 24 h; again this effect is stronger after 6 
h. However, total levels of Chk1 in its dephosphorylated form remain unchanged and as in 
U2OS cells, an induction of p53 upon gemcitabine treatment, unchanged by G2E3 
knockdown, can be seen in the HCT116 p53+/+. Taken together, these results strongly 
support the hypothesis that G2E3 is an early regulator of pChk1 in a p53 independent 
manner and make G2E3 a potential candidate for sensitising cancer cells towards 
chemotherapy by alleviating a cell’s response to DNA damaging agents such as 
chemotherapy, thus making DNA repair less likely to occur and shifting the balance more 
towards apoptosis. 
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Figure 15: Phospo-Chk1 levels decrease after knockdown of G2E3 and gemcitabine 
treatment 
U2OS (A), HCT116 p53+/+(B) and HCT116 p53-/-(C) were transiently transfected with two 
different siRNAs against G2E3 or a control siRNA, then treated with 300 nM gemcitabine 
for either 6 h or 24 h and processed for western blot analysis. Hsc70 staining was included 
as a loading control. 
3.3 MK2 inhibition rescues accumulation of  ssDNA and γ-H2AX 
upon gemcitabine treatment 
Previous work in our group (mainly conducted by Frederik Köpper and Cathrin Bierwirth) 
provided evidence for a direct impact of the p38/MK2 pathway on a cell’s response to 
replicative stress. The results of this work as well as results acquired as part of this thesis 
were published in 2013 in PNAS (Köpper et al. 2013), where it was shown that MK2 
promotes the stalling of replication forks upon DNA damage. After inhibition or siRNA 
knockdown of MK2 and treatment with gemcitabine the normally observed induction of  
γ-H2AX and decreased cell-survival is rescued. DNA fiber assays showed that MK2 is 
required for two key features of replicative stress, namely the slow-down of fork speed and 
the increase in late origin firing. These effects were dependent on translesion synthesis, a 
mechanism where cells use another polymerase that has a lower fidelity and is more error-
prone but able to continue synthesising if there are obstacles within the DNA strand that 
lead to fork stalling (Köpper et al. 2013). One of the main polymerases involved in 
translesion synthesis is polymerase η. 
Based on these results, we were interested if this function of MK2 could also be observed 
when using the accumulation of ssDNA as an indirect measure of stalled replication forks. 
Following this idea, a series of experiments was conducted were we indeed found that the 
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inhibition of MK2 leads to a significant reduction of both ssDNA and γ-H2AX in U2OS 
cells treated with gemcitabine for 24 (see Figure 16). Interestingly, when we used 
hydroxyurea as a chemotherapeutic drug instead of gemcitabine and conducted the same 
experiment, the inhibition of MK2 had no effect at all. The results of these experiments are 
shown in Figure 16. 
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Figure 16: Inhibition of MK2 rescues ssDNA and γ-H2AX after gemcitabine treatment but 
not after hydroxyurea treatment 
(A)-(E): Cells were labelled with 10 µM BrdU for 24 h and then treated with 300 µM 
gemcitabine or 2 mM hydroxyurea together with either MK2 inhibitor or DMSO as control 
for 24 hours. Cells were then harvested and co-stained for BrdU and γ-H2AX. For 
gemcitabine treatment, the inhibition of MK2 leads to a significant decrease in the amount 
of ssDNA as well as γ-H2AX as opposed to DMSO. In case of hydroxyurea the inhibition 
of MK2 does not significantly change the amount of ssDNA or BrdU. (F)-(G): All these 
effects could also be observed after 4 hours of gemcitabine or hydroxyurea treatment. 
A possible explanation for this phenomenon lies in the different mechanisms of action 
used by hydroxyurea and gemcitabine. Hydroxyurea inhibits ribonucleotide reductase, 
thereby leading to an imbalance and most importantly shortage of available nucleotides. 
While gemcitabine also to a small degree inhibits RNR, it is a nucleoside analogue that first 
and foremost leads to misincorporation and chaintermination without influencing 
nucleotide pools as much (see 1.1.2). As it has previously been shown that polymerase η 
depends on high nucleotide levels (Washington et al. 2003), we hypothesise that the 
shortage of nucleotides caused by hydroxyurea impedes translesion synthesis as much as it 
impedes normal DNA replication and therefore abolishes the target via which MK2 exerts 
its effect (Köpper et al. 2013). 
Nevertheless, the fact that the presence of MK2 together with gemcitabine treatment 
promotes replication fork stalling and accumulation of γ-H2AX makes it an interesting 
candidate to investigate in terms of resistance to chemotherapy. 
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4 Discussion 
The stalling of replication forks and slow-down of replication itself is one of the key 
features of replicative stress and can pose great obstacles that need to be overcome in order 
to maintain genome integrity and prevent malignant transformation of cells. In case of 
tumour cells that already underwent malignant transformation, the induction of replicative 
stress is one of the very principles of chemo- and radiotherapy. The process of replicating 
DNA is the most vulnerable phase during the cell cycle and the importance, implications 
and extent of replicative stress have only started to be acknowledged and understood 
during recent years. 
In this context, the work presented in this study aims to contribute to our understanding of 
the cellular processes that occur in times of replicative stress by establishing and refining a 
staining method for ssDNA in a large semi-automated setting that can also be used for 
screening analysis. This method was then employed to identify proteins that interfere with 
the accumulation of ssDNA and further investigate them. The two proteins picked were 
G2E3 and MK2. Both seem to be involved in signalling upon replicative stress but in a 
very different manner. 
We found that the knockdown of the ubiquitin ligase G2E3 leads to a much higher 
accumulation of ssDNA upon treatment with the nucleoside analogue gemcitabine. 
Moreover G2E3 seems to be a regulator of one of the most important kinases involved in 
the DNA damage response, namely Chk1. Knockdown of G2E3 reduces the 
phosphorylation and hence activation of Chk1 upon gemcitabine treatment. We also 
provide evidence that this regulation occurs in a p53 independent manner. 
We also investigated the effects of the inhibition of MK2, a kinase known to be involved in 
p38 signalling and an increasingly recognised regulator of replicative stress, on the 
accumulation of ssDNA. Inhibition of MK2 rescues the accumulation of ssDNA and       
γ-H2AX that is normally observed after treatment with gemcitabine. These results provide 
further evidence that MK2 positively regulates replication fork stalling. 
4.1 The BrdU assay as a method to assess replicative stress 
At the core of this study stands a further development of the BrdU assay for ssDNA that 
was in its first basic form originally described in 2005 (Syljuåsen et al. 2005). We could 
show that our refinements make it a suitable and relatively easy method to detect ssDNA at 
sites of replication fork stalling even in a high-content, semi-automated setup. 
Due to its characteristics the BrdU assay for ssDNA stands between the 
immunofluorescence-based detection of indirect markers of replicative stress like γ-H2AX 
4 Discussion 41 
that are often used for screening analysis because of the relatively easy staining method that 
can be applied to a large sample sizes and more in-depth tools like DNA fiber-assays that 
are much more complicated and time consuming and are therefore more useful for 
investigating proteins that are already known to be involved in processes surrounding the 
replication fork. In this study we introduced the BrdU assay in a refined form, making it 
possible to be applied in a high-content, semi-automated setup for the first time (see 3.1). 
This makes it a new and very useful tool to get a more direct readout regarding the amount 
of stalled replication forks already as part of the screening process. Additionally, it can 
easily be combined with a co-staining for γ-H2AX on the same plate. We could show that 
the BrdU signal correlates well with γ-H2AX as an established but less specific marker of 
DNA damage (Figure 10). 
It is conceivable that the induction of apoptosis could also induce an accumulation of 
ssDNA and therefore produce false positive results in the BrdU assay as apoptosis leads to 
the release of endonucleases that cut the DNA into oligonucleotide sized pieces. Apoptosis 
can be triggered from within a cell as a consequence of replicative stress or more general 
DNA damage; this makes it difficult to differentiate between accumulation of ssDNA 
caused by stalled replication forks and possible accumulation caused by apoptosis. But 
apoptosis can also be triggered via the extrinsic pathway without any form of DNA 
damaging treatment, thereby avoiding the difficulties in differentiating a signal caused by 
replicative stress from one possibly caused by apoptosis. We therefore induced apoptosis in 
U2OS cells via stimulation of their death receptors and processed them for use in the BrdU 
assay. As Figure 9 shows there is no significant increase in BrdU intensities. Beyond that, 
cells were also treated with TRAIL to stimulate death receptors and Cycloheximide to 
inhibit protein biosynthesis in parallel to intensify apoptotic stimulation. Following this 
treatment we could observe a very slight but statistically significant increase in ssDNA 
accumulation (see Figure 9). Based on these results it can be said that a small amount of 
ssDNA seems to accumulate following massive induction of apoptosis but this does not 
relevantly confound the results of the BrdU assay as it only accounts for a very minor part 
of the observed signal intensities and only occurred after massive induction of apoptosis 
and not after sole stimulation of the death receptors using TRAIL. To make sure that 
assumption is still correct in the case of G2E3 knockdown cells, we treated cells as 
normally with gemcitabine and half of them additionally with Z-VAD, an inhibitor of 
caspases to suppress apoptosis (see Figure 14). There was no significant difference between 
the cells treated with Z-VAD and the control. It can be concluded that massive apoptosis 
in general may lead to a slight increase in ssDNA as detected with the BrdU assay but 
under normal circumstances and also in the case of G2E3 this does not significantly 
confound the results. Rather, the observed accumulation of ssDNA seems for the very 
major part due to replicative stress resulting in stalled or even collapsed replication forks. 
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4.1.1 Limitations and outlook 
In order to lead to a positive signal in the BrdU assay, there need to be high enough levels 
of ssDNA. However, the assumption that replicative stress always causes enough ssDNA 
to be detectable may not be true and also the comparison with γ-H2AX levels does not 
eliminate this problem because for the phosphorylation of γ-H2AX a global response in 
the cell is necessary which may not be there but the cell may just react locally to a low level 
of replicative stress (Zeman and Cimprich 2014). Therefore, we cannot exclude that low 
levels of replicative stress may lead to too few stalled replication forks to be detectable. 
Nevertheless, this limitation is true for nearly all immunofluorescence-based assays 
regardless which target structure is stained and looked at. 
In this study, we always quantified the BrdU intensities by defining ROIs comprised of the 
cells’ nuclei, assessing intensities within them and then calculating a mean intensity per well. 
It should also be possible to actually count the number of BrdU spots within a nucleus as 
opposed to looking at intensities. This will most probably not be possible in the automated 
setting, as it requires high-resolution confocal images. Before we adapted the BrdU assay 
for use in high-content immunofluorescence, we conducted studies using cells grown on 
cover slips and stained as normal for microscopy with a Zeiss Confocal LSM 510 meta 
microscope using 63x magnification (see Figure 8 for an example picture). With these 
microscopic pictures or even higher magnification and resolution it should technically be 
possibly to segment the pictures and count individual BrdU spots that exceed a certain 
threshold signal intensity. This could provide a read-out that could allow for an even more 
direct assessment of stalled replication forks by actually counting them. 
4.2 G2E3 in the response to DNA damage 
Our results strongly suggest that G2E3 plays a role in the regulation of the ATR/Chk1 
pathway. Depletion of G2E3 via siRNA mediated knockdown leads to reduced 
phosphorylation and hence activation of Chk1 in response to replicative stress induced by 
treatment with gemcitabine. Another study conducted by Franziska Schmidt in our group, 
also found this effect after treatment with the chemotherapeutic drug cisplatin (Schmidt et 
al. 2015). To this point, the mechanism how G2E3 influences pChk1 levels remains 
unclear. It is possible that G2E3 influences upstream regulators of the ATR/Chk1 pathway 
or ATR itself but further research is needed to unveil the exact mechanism. Based on the 
results obtained so far, we propose that G2E3 normally sustains the ATR/Chk1 pathway, 
thereby avoiding replicative stress and promoting the stabilisation and restart of stalled 
replication forks, see Figure 17 for a schematic depiction. After gemcitabine or cisplatin 
treatment, G2E3 mRNA-levels significantly decrease, suggesting a down-regulation of 
G2E3 following replicative stress (Schmidt et al. 2015). This down-regulation could then 
tip the balance more towards a decrease in proliferation or even apoptosis instead of 
stabilising stalled forks, halting the cell cycle and trying to repair the damage, thereby 
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possibly generating mutations. This fits well together with the findings that G2E3 plays a 
role in cell survival and G2E3 knockout leads to early embryonic lethality based on massive 
apoptosis at the blastocyst stage in mice (see 1.3) (Brooks et al. 2008; Schmidt et al. 2015). 
 
Figure 17: Proposed model of G2E3 action in the context of replicative stress 
G2E3 normally sustains ATR/Chk1 signalling, thereby promoting stabilisation of stalled 
replication forks and halting the cell cycle in order to give the cell time to repair the damage 
and finish replication without accumulating too many mutations. Upon severe DNA 
damage though, G2E3 is downregulated and no longer positively influences ATR/Chk1 
signalling, leading to more collapsed replication forks and DNA damage in general and 
possibly shifting the balance more towards apoptosis. 
This model also explains the increased levels of ssDNA as observed in the BrdU assay. 
Chk1 is an important factor involved in the DNA damage response and also in the intra-S 
phase checkpoint. It is known that abrogation of Chk1 function leads to a massive 
accumulation of ssDNA, increased DNA synthesis that is at least partially mediated by 
increased origin firing and breakage of the DNA (Feijoo et al. 2001; Syljuåsen et al. 2005). 
This is fully compatibly with our results that G2E3 knockdown induces stalled replication 
forks upon gemcitabine treatment and also promotes phosphorylation of H2AX. 
4.2.1 G2E3 as a potential target for chemosensitisation 
Despite advancements in cancer therapy that were made during the last years, 
chemotherapy is still a key treatment for most malignancies. One way to further strengthen 
the effect of chemotherapy while simultaneously sparing healthy cells from too severe side 
effects is chemosensitisation. There are already clinical trials investigating the possibility of 
inhibiting Chk1 itself or its regulators like for example ATR in combination with 
chemotherapy (McNeely et al. 2014; Sausville et al. 2014; Daud et al. 2015; Morgan and 
Lawrence 2015). Often, these studies use gemcitabine as part of the chemotherapeutic 
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regime, the same drug that was used in this study. The fact that G2E3 knockdown leads to 
increased accumulation of ssDNA and γ-H2AX and lowers the level of phospho-Chk1 
makes it a promising target for chemosensitisation. If G2E3 is inhibited, cells accumulate 
more damage and are less likely to survive treatment. 
4.2.2 Open questions and outlook 
Based on our findings in the BrdU assay that knockdown of G2E3 in U2OS cells lead to 
an increase in ssDNA and γ-H2AX we conducted western blot experiments that showed 
the same effect for γ-H2AX. To assess the p53 dependence of this process we repeated 
these western blots in a cell-line called HCT116 that exists in a p53+/+ and a p53-/- form. 
Again, we observed an increase in γ-H2AX in G2E3 knockdown cells after treatment with 
gemcitabine, see Figure 15 for details. This is a strong hint that also the accumulation of 
ssDNA that, as we show in Figure 10, highly correlates with γ-H2AX, is not dependant on 
p53. In this context it would be very interesting to perform the BrdU assay in HCT116 
cells. Unfortunately, this was technically not possible due to the morphology of HCT116 
cells. The cell line is derived from colorectal cancer cells and the cells are very small and 
round and not very well attached to the surface they are growing on. All these features 
make them difficult to use in the BrdU assay since they are easily washed away during the 
staining procedure and the few cells that survive are so small that it is technically very 
difficult to reliably segment them and define ROIs in an automated manner. We tried 
HCT116 cells for the BrdU assay but finally could not get technically satisfying results. A 
compromise for further experiments could be to perform a double knockdown of G2E3 
and p53 in U2OS cells and assess BrdU levels there. 
We hypothesise that G2E3 influences pChk1 levels via regulation of ATR or its upstream 
regulators. To validate this assumption it will be beneficial to conduct western blot analyses 
including a staining for ATR-substrates. Antibodies that bind to ATR’s phosphorylation 
motif are commercially available and could be used additionally to pChk1 and γ-H2AX. If 
our hypothesis is correct, we would expect a decrease in phosphorylated ATR substrates 
following G2E3 knockdown and DNA damaging treatment. These studies could also help 
in the goal of finding G2E3’s natural substrates that to this point remain unknown. It is for 
example conceivable that G2E3 ubiquitinates a yet to be identified negative regulator of 
ATR that is subsequently degraded. But as of now, this remains speculation. 
Another interesting question is whether G2E3 influences progression through the cell 
cycle. It is known that depletion of G2E3 leads to a slower replication rate (Schmidt et al. 
2015) and G2E3 itself is expressed in a cell-cycle dependent manner (Crawford and 
Piwnica-Worms 2001). If G2E3 does indeed lead to a slow-down or even arrest of the cell-
cycle, this could explain the only slight induction of ssDNA and even decrease in γ-H2AX 
levels in G2E3 knockdown cells after 4 h of gemcitabine but strong increase after 24 h of 
treatment (see Figure 13). 
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4.3 MK2 and chemoresistance 
Replicative stress can lead to stalling and eventually collapse of replication forks but this 
process is not only a result of replicative stress but also tightly regulated itself. The data 
presented in this study, as well as further work conducted in our group by Frederik Köpper 
and Cathrin Bierwirth, suggest that MK2 positively regulates replication fork stalling, 
meaning that the presence of MK2 leads to a higher number of stalled forks, resulting in 
fork collapse and subsequent strand breaks, see Figure 16. Therefore, it was suggested that 
MK2 favours stalling and possible repair and restart of forks under low levels of replicative 
stress and is down regulated after DNA damage tipping the balance more towards 
translesion synthesis, thereby introducing replication errors and making it more likely for a 
cell to gain mutations (Köpper et al. 2013). The results obtained in this study further 
support this hypothesis as we could show that inhibition of MK2 rescues the normally 
observed accumulation of ssDNA as well as γ-H2AX after gemcitabine treatment. 
However, this is not true for treatment with hydroxyurea. We suggest that this is due to the 
different mechanism of action used by both drugs. Hydroxyurea leads to imbalances and 
shortages in the dNTP pool by inhibiting RNR and this likely impairs translesion synthesis, 
the very mechanism that the rescue of fork stalling upon MK2 inhibition relies on (see 3.3). 
In this context, MK2 could be a potential factor in the resistance to chemotherapy. It is 
known that tumours treated with chemotherapy often already accumulated mutations, or 
continue to do so during therapy, that impede the effect of chemotherapy. Gemcitabine, 
the drug used in this study, is part of treatment protocols for advanced solid tumours, 
especially pancreatic tumours. But even with chemotherapy the clinical outcome with these 
malignancies is poor. For pancreatic cancer, over 75 % of patients show no or only a very 
slight response with the commonly used treatment protocols and nearly all patients with 
pancreatic cancer eventually develop metastases letting the mean 5-year survival rate drop 
below 5 % (Li et al. 2004; Dhayat et al. 2011). There is already extensive research regarding 
resistance mechanisms to gemcitabine and a multitude of proteins and microRNAs 
involved in the DDR, apoptotic signalling and cell growth have been identified to play a 
role in this context. Hence, loss of MK2 could be another factor how resistance to 
gemcitabine is achieved. At least within our cell culture model the effects are highly 
significant. But more research is needed to determine whether this is also true in a more 
clinical setting. 
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5 Abstract 
Cells are constantly subjected to DNA damaging agents like reactive oxygen species, UV 
light or, in the case of cancer cells, chemotherapeutic drugs. All these agents can lead to 
replicative stress, meaning that the most sensitive part of the cell cycle, namely S phase 
where cells replicate their DNA, is compromised. Cells developed several mechanisms to 
respond to replicative stress. One of the most prominent is the stalling of replication forks. 
Stalled forks can either be rapidly stabilised and eventually restarted or they collapse, 
leaving behind unfinished sites of replication that later on need to be dealt with. The 
stalling of forks leads to the exposure of stretches of single-stranded DNA (ssDNA). In 
this study we use a new DNA staining method to detect these stretches of ssDNA and 
refine it for use in a high-content, semi-automated setup. With this method we then 
conduct a mini-screen including proteins known to be involved in the DNA damage 
response and identify two candidates that are investigated further. Knockdown of G2E3, 
an E3 ubiquitin ligase, together with gemcitabine treatment leads to much higher levels of 
ssDNA as a read-out for stalled replication forks and γ-H2AX, a well established marker of 
DNA damage. We further provide evidence that G2E3 is a novel regulator of ATR/Chk1 
signalling as it inhibits the phosphorylation and hence activation of Chk1, one of the key 
kinases of the DNA damage response. Based on these results, G2E3 is a potential new 
drug target for sensitising cancer cells for chemotherapy. The second protein investigated is 
MK2, a kinase known to be involved in signalling following DNA damage. We show that 
inhibition of MK2 rescues the normally observed induction of stalled forks and γ-H2AX 
accumulation upon gemcitabine treatment defining it as a regulator of replication fork 
stalling during replicative stress. 
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